Literature DB >> 2379532

Placental transfer and perinatal pharmacokinetics of betaxolol.

P L Morselli1, M J Boutroy, G Bianchetti, A Zipfel, J L Boutroy, P Vert.   

Abstract

Betaxolol levels in blood were monitored in the perinatal period in 28 pregnant hypertensive women and in their babies. In the mothers betaxolol concentrations at delivery ranged from less than 1 to 115 ng.ml-1 after doses of 10 to 40 mg.day-1. The apparent blood half-life was 15.6 to 22.1 h mean (19 h). Umbilical cord levels indicated a rapid equilibrium between fetal and maternal units (ratio 0.93) within few hours after dosing. Milk betaxolol concentrations, measured in few cases, exceeded those in blood by a factor of 3. Amniotic fluid concentrations were similar to those observed in maternal venous blood and umbilical cord blood. In neonates, the blood betaxolol half-life ranged from 14.8 to 38.5 h, with a definite trend towards a negative correlation with gestational age. A 11-61% rise in the betaxolol concentration was observed in 64% of the neonates during the first 12 h of extrauterine life. The data indicate that betaxolol kinetics is not altered in pregnant women and they stress the need for careful and prolonged (72-96 h) intensive monitoring of neonates born to hypertensive mothers treated with beta-blocking agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2379532     DOI: 10.1007/bf02336687

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  Simple method for routine determination of betaxolol in blood and urine by automated high-performance liquid chromatography with fluorimetric detection.

Authors:  H Caqueret; G Bianchetti
Journal:  J Chromatogr       Date:  1984-11-09

2.  Comparison of the antihypertensive effects of betaxolol to atenolol.

Authors:  W J Mroczek; J F Burris; L B Hogan; D C Citron; A H Barker; R H McDonald
Journal:  Am J Cardiol       Date:  1988-04-01       Impact factor: 2.778

Review 3.  Beta-adrenergic blockers in pregnancy.

Authors:  W H Frishman; M Chesner
Journal:  Am Heart J       Date:  1988-01       Impact factor: 4.749

4.  Beta blockers in pregnancy.

Authors:  P C Rubin
Journal:  Br J Obstet Gynaecol       Date:  1987-04

5.  Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial.

Authors:  P F Plouin; G Breart; F Maillard; E Papiernik; J P Relier
Journal:  Br J Obstet Gynaecol       Date:  1988-09

6.  Propranolol in pregnancy three year prospective study.

Authors:  I Livingstone; P W Craswell; E B Bevan; M T Smith; M J Eadie
Journal:  Clin Exp Hypertens B       Date:  1983

7.  Effects of beta 1-adrenoceptor blockade in the treatment of hypertension during pregnancy in diabetic women.

Authors:  P Olofsson; S Montan; G Sartor; N O Sjöberg
Journal:  Acta Med Scand       Date:  1986

8.  Atenolol elimination in the neonate.

Authors:  P C Rubin; L Butters; B Reynolds; J Evans; D Sumner; R A Low; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

9.  Atenolol and metoprolol. A comparison of their excretion into human breast milk.

Authors:  J Kulas; N O Lunell; U Rosing; B Stéen; A Rane
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1984

Review 10.  Pharmacokinetics of antihypertensive drugs in the neonatal period.

Authors:  P L Morselli; M J Boutroy; G Bianchetti; J P Thénot
Journal:  Dev Pharmacol Ther       Date:  1989
View more
  1 in total

Review 1.  Placental transfer of drugs administered to the mother.

Authors:  G M Pacifici; R Nottoli
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.